Author: cyb2025
Big names, big issues: Chemspec Europe 2025 to deliver strong insights and momentum at a pivotal time for the chemicals industry
30 May 2025
No Comments
From 4–5 June, the international fine and speciality chemicals industry will gather at Koelnmesse,
Fondazione Telethon submits EU marketing authorization application for Etuvetidigene Autotemcel Gene Therapy for the treatment of Wiskott-Aldrich Syndrome
30 May 2025
No Comments
Fondazione Telethon announced that it has submitted the Marketing Authorization Application (MAA) for the gene therapy
MLD and Gene Therapy: A Game-Changing Treatment Backed by NEJM—Timing Is Everything
30 May 2025
No Comments
Gene therapy has been shown to preserve motor function and cognitive abilities in the
Biologists identify targets for new pancreatic cancer treatments
30 May 2025
No Comments
Their study yielded hundreds of “cryptic” peptides that are found only on pancreatic tumor
Evolved gene editor inserts entire genes in human cells
30 May 2025
No Comments
The new system is the first to use a DNA-mobilizing enzyme called a CRISPR-associated
Flamma Published in Organic Process Research & Development (OPRD): A new method for assessing eco-impact by using both quantitative and qualitative data, focusing on process sustainability
13 May 2025
No Comments
The Flamma Group (“Flamma”), a global, fully integrated company producing and commercializing small molecule Active Pharmaceutical Ingredients (APIs) for the life science industry as well as a preeminent Contract Development..
Toxic Bloom: Where Hazardous Reagents Flourish Safely in Flow
13 May 2025
No Comments
Toxic reagents like phosgene or H₂S can be used safely in flow chemistry, boosting yield, control, and safety. Smaller equipment, higher throughput—where danger meets precision. Beauty can be lethal. Unless it’s in flow.
Porton Advanced’s End-to-End CDMO Solutions Accelerates IND Approval of Tasly’s Innovative Dual-Targeting CAR-T Therapy
12 May 2025
No Comments
April 12, 2025 – Porton Advanced proudly announces its CDMO support for TASLY PHARMACEUTICAL CO., LTD’s Innovative Dual-Targeting CAR-T Therapy, “P134 Cell Injection,” which has received Investigational New Drug (IND) approval from China’s National..
Successful Extension of Nucleic Acid Aptamer Pharmacokinetics in Joint Research by Ajinomoto Co., Inc. and RIBOMIC Inc.
12 May 2025
No Comments
As part of our efforts to demonstrate the applicability of AJICAP®, we have been advancing joint research with RIBOMIC (disclosed on December 27, 2023) aimed at realizing next-generation aptamer pharmaceuticals. In this research, RIBOMIC has..